Skip to content

The evaluation of clinical effect and safety on Advanced Gastric Cancer by Xiaotansanjie Formula combined with chemotherapy

The evaluation of clinical effect and safety on Advanced Gastric Cancer by Xiaotansanjie Formula combined with chemotherapy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IPR-17011990
Enrollment
Unknown
Registered
2017-07-14
Start date
2017-08-01
Completion date
Unknown
Last updated
2017-07-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Cancer

Interventions

treatment group:therapeutic drugs
control group:placebo

Sponsors

Traditional Chinese Medicine department of Shanghai Changzheng hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Diagnosis of gastric cancer by histopathologic histology; (2) An unresectable terminal stomach cancer combined with CT, MRI and other imaging or fall cytology, and has at least one repeatable measuring lesions; (3) The ECOG score 2 points or less, is expected to survive period of 6 months or more; (4) The multidisciplinary collaboration assessment for gastric cancer chemotherapy; (5) The patient informed and signed informed consent.

Exclusion criteria

Exclusion criteria: (1) Allergy to the research drug or any of the related ingredients; (2) Participate in other clinical studies within 1 month; (3) Combined with cardiovascular, liver, kidney, hematopoietic system or other diseases ,including psychiatric patients.

Design outcomes

Primary

MeasureTime frame
disease control rate;

Secondary

MeasureTime frame
OS;chemotherapy completion rate;quality of life;

Countries

China

Contacts

Public ContactXiaoqiang Yue

The Second Military Medical University

yuexiaoqiang@163.com+86 13917962316

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026